These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

243 related items for PubMed ID: 30094546

  • 1. Predictive value of primary tumor parameters using 18F-FDG PET/CT for occult lymph node metastasis in breast cancer with clinically negative axillary lymph node.
    Yoo J, Kim BS, Yoon HJ.
    Ann Nucl Med; 2018 Nov; 32(9):642-648. PubMed ID: 30094546
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Metabolic and volume-based parameters of (18F)FDG PET/CT for primary mass and axillary lymph node metastasis in patients with invasive ductal carcinoma: a retrospective analysis in relation to molecular subtype, axillary lymph node metastasis and immunohistochemistry and inflammatory markers.
    Can C, Komek H.
    Nucl Med Commun; 2019 Oct; 40(10):1051-1059. PubMed ID: 31365497
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Volume-based metabolic parameter of breast cancer on preoperative 18F-FDG PET/CT could predict axillary lymph node metastasis.
    An YS, Kang DK, Jung Y, Kim TH.
    Medicine (Baltimore); 2017 Nov; 96(45):e8557. PubMed ID: 29137072
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The value of primary tumor (18)F-FDG uptake on preoperative PET/CT for predicting intratumoral lymphatic invasion and axillary nodal metastasis.
    Jung NY, Kim SH, Kang BJ, Park SY, Chung MH.
    Breast Cancer; 2016 Sep; 23(5):712-7. PubMed ID: 26219608
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The clinical value of tumor FDG uptake for predicting axillary lymph node metastasis in breast cancer with clinically negative axillary lymph nodes.
    Seok JW, Kim Y, An YS, Kim BS.
    Ann Nucl Med; 2013 Jul; 27(6):546-53. PubMed ID: 23543486
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Alternative volumetric PET pjmirometers for evaluation of breast cancer cases with 18F-FDG PET/CT imaging: Metabolic tumour volume and total lesion glycolysis.
    Arslan E, Can Trabulus D, Mermut Ö, Şavlı TC, Çermik TF.
    J Med Imaging Radiat Oncol; 2021 Feb; 65(1):38-45. PubMed ID: 33084216
    [Abstract] [Full Text] [Related]

  • 12. Prognostic Value of Percentage Change in Metabolic Parameters as Measured by Dual-Time Point 18F-FDG PET/CT in Premenopausal Women with Invasive Ductal Breast Carcinoma.
    Yoo J, Yoon HJ, Kim BS.
    J Womens Health (Larchmt); 2017 Oct; 26(10):1131-1137. PubMed ID: 28498790
    [Abstract] [Full Text] [Related]

  • 13. Axillary Lymph Node-to-Primary Tumor Standard Uptake Value Ratio on Preoperative (18)F-FDG PET/CT: A Prognostic Factor for Invasive Ductal Breast Cancer.
    Kim YH, Yoon HJ, Kim Y, Kim BS.
    J Breast Cancer; 2015 Jun; 18(2):173-80. PubMed ID: 26155294
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Prognostic value of FDG-PET and DWI in breast cancer.
    Kitajima K, Miyoshi Y, Yamano T, Odawara S, Higuchi T, Yamakado K.
    Ann Nucl Med; 2018 Jan; 32(1):44-53. PubMed ID: 29134565
    [Abstract] [Full Text] [Related]

  • 16. 18F-FDG uptake by metastatic axillary lymph nodes on pretreatment PET/CT as a prognostic factor for recurrence in patients with invasive ductal breast cancer.
    Song BI, Lee SW, Jeong SY, Chae YS, Lee WK, Ahn BC, Lee J.
    J Nucl Med; 2012 Sep; 53(9):1337-44. PubMed ID: 22870824
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Prediction of breast cancer recurrence using lymph node metabolic and volumetric parameters from 18F-FDG PET/CT in operable triple-negative breast cancer.
    Kim YI, Kim YJ, Paeng JC, Cheon GJ, Lee DS, Chung JK, Kang KW.
    Eur J Nucl Med Mol Imaging; 2017 Oct; 44(11):1787-1795. PubMed ID: 28616695
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.